Cancer Anorexia Therapy Market
Anorexia is the most common symptom that cancer patients experience. The prevalence of Anorexia in cancer patients can be observed from the fact that it falls amongst the top three common symptoms in cancer patients.
The incidence of anorexia by cancer types (in advanced cancers, namely, colorectal cancer, lung cancer, pancreatic cancer, head and neck cancer, gastroesophageal cancer, and liver cancer) in the 7MM (the US, EU5 and Japan) was recorded to be 740,055 in 2020, which is further anticipated to increase during the forecast period. As per the DelveInsight, the expected launch of pipeline therapies by key players such as Helsinn Group, Artelo Biosciences, and NGM Biopharmaceuticals will accelerate the Cancer Anorexia market growth at a CAGR of 10.92% for the forecast period 2021-30.
For more details, visit Cancer Anorexia Therapy Market